Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Recruiting 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 48Prostatic Neoplasms, Castration-Resistant 3Adenocarcinoma 3Urogenital Neoplasms 2Salivary Gland Neoplasms 2Prostatic Diseases 2Non-metastatic Castration-resistant Prostate Cancer 2Neoplasms 2Neoplasm Metastasis 2Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 2Metastatic Castration-resistant Prostate Cancer 2Male Urogenital Diseases 2Bulbo-Spinal Atrophy, X-Linked 2Biochemically Recurrent Prostate Cancer 2Urogenital Diseases 1Triple Negative Breast Neoplasms 1Sleep Initiation and Maintenance Disorders 1Refractory or Relapsed Solid Tumors 1Prostate Cancer Metastatic 1Prostate Adenocarcinoma 1Neoplasms by Site 1Metastatic Hormone-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Neoplasms 1High-Risk Localized Prostate Cancer 1Granulosa cell tumor of the ovary 1Genital Diseases, Male 1Fatigue 1Depression 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1

Interventions

enzalutamide 10Prednisone 6Docetaxel 5Abiraterone Acetate 4darolutamide 3olaparib 2niraparib 2abiraterone 2Pluvicto 2zimberelimab 1xentuzumab 1sacituzumab govitecan 1radium Ra 223 dichloride 1quemliclustat 1ibrutinib 1gedatolisib 1gallium 68 PSMA-11 1fludrocortisone acetate 1cabazitaxel 1TVB-2640 1Rosuvastatin Calcium 1Pioglitazone 1Omeprazole 1Nivolumab 1JNJ-64619178 1JNJ-64264681 1Ipilimumab 1Gonadotropin-Releasing Hormone 1Dexamethasone 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Prostatic Neoplasms, Castration-Resistant × darolutamide × 1 year × Clear all
NCT05997615 2026-06-04

AMX-500

Vir Biotechnology, Inc.

Phase 1 Recruiting
437 enrolled
Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT06190899 2026-04-13

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Celcuity Inc

Phase 1/2 Recruiting
54 enrolled
Genitourinary

Genital Diseases, Male, Prostatic Diseases, Prostatic Neoplasms, Male Urogenital Diseases, Prostatic Neoplasms, Castration-Resistant

NCT05519449 2026-01-20

ENGAGER-PSMA-01

Janux Therapeutics

Phase 1 Recruiting
272 enrolled
Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡